A new study suggests that a common allergy nasal spray may reduce COVID-19 infections by 67%. With limited vaccine access, could this over-the-counter solution be the future of viral protection?
A new phase 2 trial reveals that a single dose of psilocybin, combined with psychological support, significantly reduces depression in over half of cancer patients, lasting up to two years.
